Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.76 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.72 |
| ▸ | ASAH2 | Q9NR71 | 2/20 | 0.69 |
| ▸ | PLA2G4A | P47712 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167971 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL20152381 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL31276708 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL30915241 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL13587670 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL2734386 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL31277312 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL31277666 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL20450780 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 | |
| SCHEMBL30498995 | 1.00 | CETP (0.97) | CETPTHRBMEN1KMT2AASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074989-A1 | METHODS AND COMPOSITIONS FOR TREATING PANCREATIC DISEASE | METANOIA BIO INC (US) | 2025-03-06 | — | — | US | claimed |
| CN-119355184-A | Parkinson disease biomarker, detection reagent and application | 渤海(天津)医疗科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| WO-2024216751-A1 | RISK PREDICTION MODEL OPERATION MODULE, AND RISK PREDICTION SYSTEM FOR ACUTE CORONARY SYNDROME | 南京品生医疗科技有限公司 | 2024-10-24 | — | — | WO | claimed |
| CN-118609835-A | Construction method of coronary plaque stability prediction model based on ceramide | 北京市心肺血管疾病研究所 | 2024-09-06 | — | — | CN | claimed |
| CN-118425358-A | Use of lipid markers in detection of polycystic ovary syndrome | 北京大学第三医院（北京大学第三临床医学院） | 2024-08-02 | — | — | CN | claimed |
| US-20230324419-A1 | METHOD FOR DIAGNOSING ACTING OF NERVONIC ACID AND USE THEREOF | BAO FENG BIOTECH (BEIJING) CO., LTD (CN) | 2023-10-12 | — | — | US | claimed |
| EP-4228667-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | Brightseed, Inc. (US) | 2023-08-23 | — | — | EP | claimed |
| CN-116568319-A | Method for reversing hepatic steatosis | 布莱特西德公司 | 2023-08-08 | — | — | CN | claimed |
| US-20230093131-A1 | ASSESSING AND TREATING ALCOHOL-ASSOCIATED LIVER DISEASE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2023-03-23 | — | — | US | claimed |
| US-11529370-B2 | Use of composition comprising stem cell-derived exosome as effective ingredient in strengthening skin barrier and improving skin barrier function | EXOCOBIO INC. (KR) | 2022-12-20 | — | — | US | claimed |
| US-20220362177-A1 | CERAMIDE RATIOS AS PREDICTIVE AND THERAPEUTIC BIOMARKERS FOR LEUKEMIAS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-11-17 | — | — | US | claimed |
| WO-2022081567-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | BRIGHTSEED, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| CN-114354775-A | Method for constructing and applying acute coronary syndrome diagnosis model | 江苏品生医疗科技集团有限公司 | 2022-04-15 | — | — | CN | claimed |
| WO-2022033576-A1 | METHOD FOR DIAGNOSING ACTING OF NERVONIC ACID, AND APPLICATION THEREOF | 宝枫生物科技（北京）有限公司 | 2022-02-17 | — | — | WO | claimed |
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-05-19 | — | — | US | disclosed |
| CN-121914887-A | Recombinant lipolytica saccharomyces cerevisiae engineering strain for producing nervonic acid and application | 江南大学 | 2026-04-24 | — | — | CN | disclosed |
| US-12590320-B2 | Cellular models of and therapies for ocular diseases | REFLECTION BIOTECHNOLOGIES LIMITED (HK) | 2026-03-31 | — | — | US | disclosed |
| WO-2022033576-A1 | METHOD FOR DIAGNOSING ACTING OF NERVONIC ACID, AND APPLICATION THEREOF | 宝枫生物科技（北京）有限公司 | 2022-02-17 | — | — | WO | disclosed |
| US-20210015767-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2021-01-21 | — | — | US | disclosed |
| US-20200407252-A1 | METHODS AND USES OF DISSOLVED ORGANIC MATERIAL FRACTIONS FOR BINDING METAL IONS | TRENT UNIVERSITY (CA) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | S1PR2, S1PR3, S1PR1 | CETP 90/4885THRB 914/4885MEN1 1287/4885 |
| US-20210015767-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | SPHK2, SPHK1, S1PR2 | CETP 80/4885THRB 4466/4885MEN1 579/4885 |
| US-12590320-B2 | Cellular models of and therapies for ocular diseases | ALDH1A2, NR2E3, RBP4 | CETP 2083/4885THRB 168/4885MEN1 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.